$2.45
-0.11 (-4.30%)
Open$2.56
Previous Close$2.56
Day High$2.58
Day Low$2.39
52W High$2.79
52W Low$0.96
Volume—
Avg Volume6.94M
Market Cap57.54M
P/E Ratio—
EPS$-2.50
SectorBiotechnology
Analyst Ratings
Strong Sell
7 analysts
Price Target
+397.6% upside
Current
$2.45
$2.45
Target
$12.19
$12.19
$8.12
$12.19 avg
$14.26
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 3.46M | 3.60M | 3.02M |
| Net Income | 357.4K | 374.4K | 370.1K |
| Profit Margin | 10.3% | 10.4% | 12.2% |
| EBITDA | 792.9K | 795.7K | 655.2K |
| Free Cash Flow | 311.9K | 219.4K | 229.2K |
| Rev Growth | +0.8% | +2.8% | +23.9% |
| Debt/Equity | 0.35 | 0.28 | 0.30 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $251.64 | -1.05% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $362.12 | +0.44% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.34 | +0.01% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $496.73 | -0.58% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $623.54 | -1.31% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $301.03 | +2.56% | 69.3 | 39.97B |